Apimeds Pharmaceuticals US, Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APUS research report →
Price Chart
About the company
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey.
- CEO
- Vinod Menon
- IPO
- 2025
- Employees
- 7
- HQ
- Matawan, NJ, US
Get TickerSpark's AI analysis on APUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.34M
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.98%
- ROIC
- -15.89%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-5,706+0.0%
- Op Income
- $-11,912,562
- Net Income
- $-6,001,137-331.7%
- EPS
- $-5.50+54.2%
- OCF Growth
- -1116.8%
- FCF Growth
- -1124.6%
- 52W High
- $59.70
- 52W Low
- $2.17
- 50D MA
- $5.57
- 200D MA
- $13.96
- Beta
- 0.15
- RSI (14)
- 24
- Avg Volume
- 72.74K
No earnings-call transcripts are available for APUS yet.
- Free Float
- 37.3%
- Shares Outstanding
- 1.51M
- Float Shares
- 563.19K
of shares held by institutions
6 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hemenway Trust Co LLC | 274.00K | 0 |
| Vanguard Capital Management LLC | 63.65K | ▼ 32.27K |
| Vanguard Group Inc | 58.99K | 0 |
| Geode Capital Management, LLC | 35.11K | ▼ 4.94K |
| Vanguard Fiduciary Trust Co | 24.04K | 0 |
| Jane Street Group, LLC | 15.99K | ▲ 15.99K |
| Ubs Group AG | 11.82K | ▲ 7.63K |
| Tower Research Capital LLC (Trc) | 1.66K | ▲ 1.66K |
Held by 7 ETFs
Biggest fund positions in APUS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 24 | Inscobee Inc. | other | 0 |
| Nov 11, 25 | Weintraub Bennett | other | 10,000 |
| Nov 11, 25 | Yoon Hankil | other | 10,000 |
| Nov 11, 25 | Koo Jakap | other | 10,000 |
| Nov 11, 25 | O'DONNELL CAROL A | other | 10,000 |
| Nov 11, 25 | Kogan Elona | other | 10,000 |
| Oct 15, 25 | Kogan Elona | other | 3,000 |
| Oct 15, 25 | O'DONNELL CAROL A | other | 3,000 |
| Oct 15, 25 | Koo Jakap | other | 3,000 |
| Oct 15, 25 | Weintraub Bennett | other | 3,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APUS coverage
Recent articles, reports, and earnings notes.
No research on APUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APUS report →NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange
globenewswire.com · Aug 3
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October
globenewswire.com · Jul 28
For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification
prnewswire.com · Jun 8
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
businesswire.com · May 5
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
globenewswire.com · Apr 26
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
globenewswire.com · Apr 26
Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
businesswire.com · Apr 16
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
businesswire.com · Apr 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.